Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May:4:100098.
doi: 10.1016/j.lanepe.2021.100098. Epub 2021 May 2.

Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults

Helen Ward  1   2   3 , Graham S Cooke  4   2 , Christina Atchison  1   2 , Matthew Whitaker  1 , Joshua Elliott  1 , Maya Moshe  4 , Jonathan C Brown  4 , Barnaby Flower  4   2 , Anna Daunt  4   2 , Kylie Ainslie  1   3 , Deborah Ashby  1 , Christl A Donnelly  1   3   5 , Steven Riley  1   3 , Ara Darzi  6   2 , Wendy Barclay  4 , Paul Elliott  1   2   7   8   9
Affiliations

Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults

Helen Ward et al. Lancet Reg Health Eur. 2021 May.

Abstract

Background: The time-concentrated nature of the first wave of the COVID-19 epidemic in England in March and April 2020 provides a natural experiment to measure changes in antibody positivity at the population level before onset of the second wave and initiation of the vaccination programme.

Methods: Three cross-sectional national surveys with non-overlapping random samples of the population in England undertaken between late June and September 2020 (REACT-2 study). 365,104 adults completed questionnaires and self-administered lateral flow immunoassay (LFIA) tests for IgG against SARS-CoV-2.

Findings: Overall, 17,576 people had detectable antibodies, a prevalence of 4.9% (95% confidence intervals 4.9, 5.0) when adjusted for test characteristics and weighted to the adult population of England. The prevalence declined from 6.0% (5.8, 6.1), to 4.8% (4.7, 5.0) and 4.4% (4.3, 4.5), over the three rounds of the study a difference of -26.5% (-29.0, -23.8). The highest prevalence and smallest overall decline in positivity was in the youngest age group (18-24 years) at -14.9% (-21.6, -8.1), and lowest prevalence and largest decline in the oldest group (>74 years) at -39.0% (-50.8, -27.2). The decline from June to September 2020 was largest in those who did not report a history of COVID-19 at -64.0% (-75.6, -52.3), compared to -22.3% (-27.0, -17.7) in those with SARS-CoV-2 infection confirmed on PCR.

Interpretation: A large proportion of the population remained susceptible to SARS-CoV-2 infection in England based on naturally acquired immunity from the first wave. Widespread vaccination is needed to confer immunity and control the epidemic at population level.

Funding: This work was funded by the Department of Health and Social Care in England.

PubMed Disclaimer

Conflict of interest statement

CAD reports grants from UK Medical Research Council, grants from UK NIHR, during the conduct of the study; HW and PE report grants from the Department of Health and Social Care during the conduct of this study. The remaining authors have nothing to disclose.

Figures

Fig. 1
Fig. 1
Prevalence of antibody positivity to SARS-CoV-2 using LFIA test, by round of study (95% confidence intervals) by sex, age group, ethnicity, employment, history of COVID-19, symptom severity. Legend: Dates: Round 1 (20 June – 13 July 2020), Round 2 (31 July–13 August 2020), Round 3 (15–28 September 2020). Bars show antibody positivity by round of study for each category of covariate with 95% confidence intervals indicated in the error bars. NB: y axis scale is different for each row. All estimates of prevalence (95% confidence intervals) are adjusted for imperfect test sensitivity and specificity, and re-weighted to account for sample design and for variation in response rate (age, sex, ethnicity, region and deprivation) to be representative of the England population (18+). Full data shown in Supplementary Table S3.
Fig. 2
Fig. 2
Epidemic curve reconstructed from reported date of onset from 11,908 IgG antibody positive people who reported symptoms, by round of study1. Legend: Seven-day rolling average of number of infections (by day of onset) in 11,908 participants testing positive for antibodies and who reported a date of onset for symptoms of COVID19, shown separately for each round. 3,759 symptomatic cases were recorded in round 1 (from 99,908 tested); 3,363 were recorded in round 2 (from 105,829 tested); and 4,786 were recorded in round 3 (from 159,367 tested). 1 See Table 1 for dates of rounds.
Fig. 3
Fig. 3
Association of LFIA result with virus micro-neutralisation titre in 49 healthcare workers with RT-PCR-confirmed SARS-CoV-2 infection. Legend: Virus micro-neutralisation titre, log scale y-axis, by LFIA results, x-axis, in 49 healthcare workers with RT-PCR confirmed SARS-CoV-2 infection. Serum samples were assayed by live virus neutralisation assay and tested by Fortress LFIA. The median for those with a negative test (n=9) was less than 10 (lower limit of detection denoted by dotted line), and for those with a positive test (n=40) it was 1:40. Mann-Whitney test z-score =3.68, two-sided P= 0.00024. LFIA (lateral flow immunoassay).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alter G, Seder R. The power of antibody-based surveillance. N Engl J Med. 2020 doi: 10.1056/NEJMe2028079. [Internet]. Sep 1 [cited 2020 Oct 26]; Available from: - DOI - PMC - PubMed
    1. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med. 2020 doi: 10.1056/NEJMoa2026116. [Internet]Sep 1 [cited 2020 Oct 26]; Available from. - DOI - PMC - PubMed
    1. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet Lond Engl. 2020 Jul 3. - PMC - PubMed
    1. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA. Rapid Decay of Anti–SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020;383(11):1085–1087. Sep 10. - PMC - PubMed
    1. Patel MM, Thornburg NJ, Stubblefield WB, Talbot HK, Coughlin MM, Feldstein LR. Change in antibodies to SARS-CoV-2 Over 60 days among health care personnel in Nashville, Tennessee. JAMA. 2020 https://jamanetwork.com/journals/jama/fullarticle/2770928 [Internet]Sep 17 [cited 2020 Oct 3]; Available from: - PMC - PubMed